5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

NCT00339196 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukaemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions

DRUG: 5 azacytidine - VALPROIC acid- Retinoic acid

Sponsor

Assistance Publique - Hôpitaux de Paris